All In Biotech

Drug Trial Radar · NCT02510261

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study

Last checked: Nov 19, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

211

Actual

Start

Jul 16, 2015

Primary completion

Nov 23, 2022

Study completion Nov 23, 2022

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Jul 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).

Conditions

  • Amyloidosis

Interventions

  • PatisiranDrug

    Patisiran was administered IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AEs) Leading to Study DiscontinuationTime frame: First dose up to 28 days after last dose of study drug (approximately 5.6 years)

Locations

56 sites in 21 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    La Mesa, California

  • Clinical Trial Site

    Aurora, Colorado

  • Clinical Trial Site

    Jacksonville, Florida

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Detroit, Michigan

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    Joplin, Missouri

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    Cooperstown, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Columbus, Ohio

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Westmead, Australia

  • Clinical Trial Site

    Rio de Janeiro, Brazil

  • Clinical Trial Site

    São Paulo, Brazil

  • Clinical Trial Site

    Sofia, Bulgaria

  • Clinical Trial Site

    Vancouver, British Columbia, Canada

  • Clinical Trial Site

    Nicosia, Cyprus

  • Clinical Trial Site

    Créteil, France

  • Clinical Trial Site

    Le Kremlin-Bicêtre, France

  • Clinical Trial Site

    Lille, France

  • Clinical Trial Site

    Marseille, France

  • Clinical Trial Site

    Fort de France, Martinique, France

  • Clinical Trial Site

    Saint-Pierre, Reunion Island, France

  • Clinical Trial Site

    Cologne, Germany

  • Clinical Trial Site

    Heidelberg, Germany

  • Clinical Trial Site

    Münster, Germany

  • Clinical Trial Site

    Pavia, Italy

  • Clinical Trial Site

    Rome, Italy

  • Clinical Trial Site

    Sicily, Italy

  • Clinical Trial Site

    Ehime, Japan

  • Clinical Trial Site

    Fukuoka, Japan

  • Clinical Trial Site

    Hiroshima, Japan

  • Clinical Trial Site

    Kumamoto, Japan

  • Clinical Trial Site

    Nagano, Japan

  • Clinical Trial Site

    Ōita, Japan

  • Clinical Trial Site

    Okawasuji, Japan

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.